Objective To investigate the expression and significance of myeloid cell leukemia-1 (Mcl-1 )gene and protein in Hepatocellular Carcinoma(HCC).Methods The expression of Mcl-1 was detected respectively by Reverse Transcription-Polymerase Chain Reaction (RT-PCR),Western blot and ENVISION immunohistochemistry in 20 HCC specimens,19 liver cirrhosis(LC)specimens,and 12 control ones.Their relationship with clinical and pathological characteristics of HCC was investigated.Results The expression of Mcl-1 mRNA in the control group,LC group and HCC group was 0.52±0.17, 3.46±1.7,3.65±2.93,respectively.The level in HCC and LC group was statistically different compared with the control group,respectively (t=7.925,5.334,P<0.05).The relative expression of Mcl-1 protein in LC group (0.51±0.35)and HCC group (0.75±0.36)were significantly higher than that in the control group (0.21±0.19)(t=5.526,6.355,P<0.05).The positive expression rate of Mcl-1 in HCC group was 55.00% (11/20),significantly higher than that in the con-trol group 33.33% (4/12)(t=7.835,P<0.05).The positive expression of Mcl-1 was related to tumor necrosis and TNM staging (χ2=4.201,P<0.05).Conclusion Mcl-1 gene and protein are differentially expressed in HCC,LC and the control, which may be involved in the occurrence,development and malignant transformation of HCC.%目的探讨髓样细胞白血病-1（myeloid cell leukemia-1，Mcl-1）基因及蛋白在原发性肝癌和肝硬化组织中的表达及临床病理学意义。方法采用逆转录-聚合酶链反应（reverse transcription-polymerase chain reaction，RT-PCR）法，蛋白质印迹法（western blot，WB）和免疫组织化学 ENVISION法分别检测20例肝癌组织，19例肝硬化组织和12例对照肝组织中 Mcl-1的表达，并分析其表达与肝癌临床病理学特征的关系。结果 Mcl-1 mRNA相对表达强度在对照组、肝硬化组和肝癌组中分别为0.52±0.17，3.46±1.7，3.65±2.93，其中肝癌组及肝硬化组分别与对照组间比较，差异均有统计学意义（t＝7.925，5.334，P＜0.05）。Mcl-1蛋白相对表达量在肝硬化组（0.51±0.35）和肝癌组（0.75±0.36）均显著高于对照组（0.21±0.19）（t＝5.526和6.355，P＜0.05）。肝癌组Mcl-1的阳性表达率为55.00％（11／20），显著高于对照组33.33％（4／12）（t＝7.835，P＜0.05），Mcl-1蛋白阳性表达与肿瘤有无坏死和TNM分期有关（χ2＝4.201，P＜0.05）。结论 Mcl-1基因及蛋白在肝癌组、肝硬化组和对照肝组织中的表达存在差异，可能参与了肝硬化的发生、发展及向肝癌的恶性转化。
展开▼
